Ruxolitinib: A new hope for ventilator‐induced diaphragm dysfunction
Acta Physiologica · 2024-05 · 240 (5)
DOI: 10.1111/apha.14128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Physiologica, online erschienen am 29.03.2024. Verfasst von Alex B Addinsall und 10 weiteren Autor:innen. Beteiligte Einrichtung: Basic and Clinical Muscle Biology, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. Hauptthemen laut MEDLINE: Diaphragm, Pyrimidines, Nitriles, Respiration, Artificial. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Noaber Foundation, Loo and Hans Osterman Foundation, Robert J. and Theresa W. Ryan.
Abstract (Originalsprache)
Aim
Mechanical ventilation (MV) results in diminished diaphragm size and strength, termed ventilator‐induced diaphragm dysfunction (VIDD). VID increases dependence, prolongs weaning, and increases discharge mortality rates. The Janus kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway is implicated in VIDD, upregulated following MV. JAK/STAT inhibition alleviates chronic muscle wasting conditions. This study aimed to explore the therapeutic potential of Ruxolitinib, an FDA approved JAK1/2 inhibitor (JI) for the treatment of VIDD.
Methods
Rats were subjected to 5 days controlled MV (CMV) with and without daily Ruxolitinib gavage. Muscle fiber size and function were assessed. RNAseq, mitochondrial morphology, respirometry, and mass spectrometry were determined.
Results
CMV significantly reduced diaphragm size and specific force by 45% ( p < 0.01), associated with a two‐fold P‐STAT3 upregulation ( p < 0.001). CMV disrupted mitochondrial content and reduced the oxygen consumption rate ( p < 0.01). Expression of the motor protein myosin was unaffected, however CMV alters myosin function via post‐translational modifications (PTMs). Daily administration of JI increased animal survival (40% vs. 87%; p < 0.05), restricted P‐STAT3 ( p < 0.001), and preserved diaphragm size and specific force. JI was associated with preserved mitochondrial content and respiratory function ( p < 0.01), and the reversal or augmentation of myosin deamidation PTMs of the rod and head region.
Conclusion
JI preserved diaphragm function, leading to increased survival in an experimental model of VIDD. Functional enhancement was associated with maintenance of mitochondrial content and respiration and the reversal of ventilator‐induced PTMs of myosin. These results demonstrate the potential of repurposing Ruxolitinib for treatment of VIDD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Basic and Clinical Muscle Biology, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.
- Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden.
- Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institute, Stockholm, Sweden.
- Division of Cardiovascular Medicine, Department of Medicine, Solna, Karolinska Institute, Sweden.
- Department of Chemistry-BMC, Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden.
- Muscle Biology Program, Viron Molecular Medicine Institute, Boston, Massachusetts, USA.
Förderung
- Noaber Foundation
- Loo and Hans Osterman Foundation
- Robert J. and Theresa W. Ryan
- Connor Fund
- Erling-Persson Foundation
- Swedish Heart and Lung Foundation
- Centrum för Idrottsforskning
- Stockholm City Council
Zitieren
APA
Addinsall, A. B., Cacciani, N., Moruzzi, N., Akkad, H., Maestri, A., Berggren, P. O., Widegren, A., Bergquist, J., Tchkonia, T., Kirkland, J. L., & Larsson, L. (2024). Ruxolitinib: A new hope for ventilator‐induced diaphragm dysfunction. Acta Physiologica, 240(5). https://doi.org/10.1111/apha.14128
Vancouver
Addinsall AB, Cacciani N, Moruzzi N, Akkad H, Maestri A, Berggren PO, et al. Ruxolitinib: A new hope for ventilator‐induced diaphragm dysfunction. Acta Physiologica. 2024;240(5). doi:10.1111/apha.14128
BibTeX
@article{Addinsall2024,
author = {Addinsall, Alex B and Cacciani, Nicola and Moruzzi, Noah and Akkad, Hazem and Maestri, Alice and Berggren, Per-Olof and Widegren, Anna and Bergquist, Jonas and Tchkonia, Tamara and Kirkland, James L and Larsson, Lars},
title = {Ruxolitinib: A new hope for ventilator‐induced diaphragm dysfunction},
journal = {Acta Physiologica},
year = {2024},
volume = {240},
number = {5},
doi = {10.1111/apha.14128}
}
EUVIMED